Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
444 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05071053 | Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer(CARMEN-GC01) | terminated | Phase 2 | 35 | SanofiINDUSTRY | 6 | Aug 22, 2025 | clinicaltrials |
| NCT06508489 | A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies | terminated | Phase 1 / Phase 2 | 7 | SanofiINDUSTRY | 2 | Aug 22, 2025 |
| NCT03324113 | Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 34 | SanofiINDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT03816839 | Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)(AMEERA-2) | terminated | Phase 1 | 10 | SanofiINDUSTRY | 1 | Jul 7, 2025 | clinicaltrials |
| NCT04394624 | Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)(CARMEN-LC04) | terminated | Phase 2 | 31 | SanofiINDUSTRY | 6 | Jun 6, 2025 | clinicaltrials |
| NCT04418661 | Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies | terminated | Phase 1 / Phase 2 | 65 | SanofiINDUSTRY | 7 | May 29, 2025 | clinicaltrials |
| NCT05429762 | Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors(TusaRav-QT) | terminated | Phase 1 | 56 | SanofiINDUSTRY | 5 | Apr 6, 2025 | clinicaltrials |
| NCT02187848 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 254 | SanofiINDUSTRY | 5 | Feb 10, 2025 | clinicaltrials |
| NCT05178745 | Resection Observatory | completed | — | 140 | SanofiINDUSTRY | 0 | Jan 30, 2025 | clinicaltrials |
| NCT02990338 | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients(ICARIA-MM) | completed | Phase 3 | 307 | SanofiINDUSTRY | 24 | Jan 17, 2025 | clinicaltrials |
| NCT00418886 | Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients(ZEAL) | completed | Phase 3 | 698 | Genzyme, a Sanofi CompanyINDUSTRY | 21 | Dec 31, 2024 | clinicaltrials |
| NCT01945762 | Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer(Caprelsa104) | completed | — | 31 | Genzyme, a Sanofi CompanyINDUSTRY | 8 | Dec 18, 2024 | clinicaltrials |
| NCT01084252 | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | completed | Phase 1 / Phase 2 | 351 | SanofiINDUSTRY | 17 | Nov 1, 2024 | clinicaltrials |
| NCT01876784 | Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer(VERIFY) | completed | Phase 3 | 238 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | Jul 23, 2024 | clinicaltrials |
| NCT03194867 | Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | completed | Phase 1 / Phase 2 | 109 | SanofiINDUSTRY | 10 | Jun 14, 2024 | clinicaltrials |
| NCT00537095 | Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer | completed | Phase 2 | 164 | Genzyme, a Sanofi CompanyINDUSTRY | 7 | Apr 19, 2024 | clinicaltrials |
| NCT02812706 | Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients(Islands) | completed | Phase 1 / Phase 2 | 36 | SanofiINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05726682 | A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) | withdrawn | Phase 2 | 0 | SanofiINDUSTRY | 0 | Mar 5, 2024 | clinicaltrials |
| NCT01515748 | Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer(PRODIGY) | completed | Phase 3 | 530 | SanofiINDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03733717 | Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 25 | SanofiINDUSTRY | 1 | Sep 8, 2023 | clinicaltrials |
| NCT05493826 | Real World Study on the Use of Cemiplimab in Adult Patients in UK(REACT-CEMI) | completed | — | 110 | SanofiINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT01749969 | SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients | completed | Phase 1 | 57 | SanofiINDUSTRY | 1 | Jul 13, 2023 | clinicaltrials |
| NCT03637764 | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 107 | SanofiINDUSTRY | 8 | Jul 10, 2023 | clinicaltrials |
| NCT05302297 | Comparative Efficacy of Cemiplimab to Historical Standard of Care in France(TOSCA) | completed | — | 305 | SanofiINDUSTRY | 1 | Dec 13, 2022 | clinicaltrials |
| NCT01440179 | SAR3419 in Acute Lymphoblastic Leukemia(MYRALL) | terminated | Phase 2 | 100 | SanofiINDUSTRY | 2 | Sep 21, 2022 | clinicaltrials |
| NCT00687765 | Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 / Phase 2 | 126 | SanofiINDUSTRY | 1 | Sep 14, 2022 | clinicaltrials |
| NCT00042341 | Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 60 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03594955 | First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 7 | SanofiINDUSTRY | 2 | May 24, 2022 | clinicaltrials |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 44 | SanofiINDUSTRY | 5 | May 16, 2022 | clinicaltrials |
| NCT03449758 | Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis(SariPRO) | completed | Phase 4 | 84 | SanofiINDUSTRY | 1 | Apr 28, 2022 | clinicaltrials |
| NCT02514668 | A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma | completed | Phase 1 | 55 | SanofiINDUSTRY | 3 | Apr 25, 2022 | clinicaltrials |
| NCT04349306 | Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia(RAISE) | completed | Phase 4 | 50 | SanofiINDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT01587040 | Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen | completed | Phase 1 / Phase 2 | 61 | SanofiINDUSTRY | 4 | Apr 19, 2022 | clinicaltrials |
| NCT00531232 | A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS) | completed | Phase 2 | 38 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT02999633 | Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia(ISLAY) | terminated | Phase 2 | 14 | SanofiINDUSTRY | 7 | Mar 21, 2022 | clinicaltrials |
| NCT02984683 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 23 | SanofiINDUSTRY | 5 | Sep 8, 2021 | clinicaltrials |
| NCT02283775 | SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients(PomdeSAR) | completed | Phase 1 | 54 | SanofiINDUSTRY | 1 | Jul 9, 2021 | clinicaltrials |
| NCT02608125 | A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma | terminated | Phase 1 | 45 | Principia Biopharma, a Sanofi CompanyINDUSTRY | 2 | Dec 24, 2020 | clinicaltrials |
| NCT00002348 | A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01596270 | A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 49 | SanofiINDUSTRY | 1 | Oct 28, 2020 | clinicaltrials |
| NCT01308567 | Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer(FIRSTANA) | completed | Phase 3 | 1,168 | SanofiINDUSTRY | 25 | Jun 5, 2019 | clinicaltrials |
| NCT00003821 | Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer | withdrawn | Phase 2 | 0 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00005645 | ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment | withdrawn | Phase 2 | 0 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00003713 | Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 35 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 29, 2018 | clinicaltrials |
| NCT00003822 | SR-45023A in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 29, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials